Update in Osteoporosis

Arthritis Care and Research

Volumn 49, Issue 5, 2003, Pages 732-734

  Buckley, Lenore ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PROGESTERONE; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE DENSITY; BONE MINERAL; BREAST CANCER; CLINICAL TRIAL; ENTERITIS; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS IRRITATION; ESTROGEN THERAPY; FEVER; FRACTURE; HUMAN; ISCHEMIC HEART DISEASE; MYALGIA; NAUSEA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

EID: 0142063450     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11375     Document Type: Review

References (12)

1. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone density. N Engl J Med 2002;346:653-661.
2. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women. N Engl J Med 2001;344:1434-1441.
3. Finkelstein J, et al. J Bone Min Res 2002;17 Suppl 1:S127.
4. Neer R. J Bone Min Res 2002;17 Suppl 1:S135.
5. Orwoll ES, Scheele WT, Paul S, Adami S, Syvelsen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17.
6. Teriparatide (Forteo) for osteoporosis. Medical Letter 2003;45: 9-10.
7. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288;321-33.
8. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow up (HERSII). JAMA 2002;288:49-57.
9. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Noncardiac disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow up (HERS II). JAMA 2002;288:58-66.
10. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-76.
11. Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial. Ann Intern Med 1999;130:897-904.
12. Cummings SR, Bates D, Black D. Clinical use of bone densitometry: scientific review. JAMA 2002;288:1889-97.